Dr Su currently serves as Chief Executive Officer and Chief Scientific Officer of HUTCHMED. Dr Su has headed all drug discovery and research since he joined HUTCHMED, including master-minding the scientific strategy of HUTCHMED, being a key leader of the Oncology/Immunology platform, and responsible for the discovery of small molecule drug candidates in the company’s pipeline. He has been continuously making efforts to advance 13 innovative oncology drug candidates into global clinical trials, among which 3 have been approved and launched in Chinese market and entered into global late-stage clinical development.

In 2017, Dr Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China; and China’s Top 10 Most Influential People in Medical and Pharmaceutical Industry of the 13th Healthy China Forum hosted by People’s Daily. He was also awarded as one of the Outstanding Innovative Entrepreneurs of Zhangjiang National Innovation Demonstration Zone in 2021.